Morgan Stanley
ADCT icon

Morgan Stanley’s ADC Therapeutics ADCT Stock Holding History

Morgan Stanley’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.3M Buy
3,812,582
+42,839
+1% +$169K ﹤0.01% 3259
2025
Q4 		$13.3M Buy
3,769,743
+100,676
+3% +$409K ﹤0.01% 3343
2025
Q3 		$14.7M Buy
3,669,067
+623,494
+20% +$1.97M ﹤0.01% 3191
2025
Q2 		$8.16M Buy
3,045,573
+25,988
+0.9% +$54.7K ﹤0.01% 3626
2025
Q1 		$4.26M Sell
3,019,585
-936,587
-24% -$1.59M ﹤0.01% 4061
2024
Q4 		$7.87M Buy
3,956,172
+915,378
+30% +$2.4M ﹤0.01% 3603
2024
Q3 		$9.58M Buy
3,040,794
+75,565
+3% +$238K ﹤0.01% 3461
2024
Q2 		$9.37M Buy
2,965,229
+244,834
+9% +$973K ﹤0.01% 3374
2024
Q1 		$12.2M Buy
2,720,395
+1,156,521
+74% +$4.27M ﹤0.01% 3177
2023
Q4 		$2.6M Buy
1,563,874
+899,847
+136% +$830K ﹤0.01% 4777
2023
Q3 		$596K Buy
664,027
+11,249
+2% +$15K ﹤0.01% 5087
2023
Q2 		$1.4M Buy
652,778
+214,829
+49% +$483K ﹤0.01% 4627
2023
Q1 		$854K Buy
437,949
+87,176
+25% +$322K ﹤0.01% 4944
2022
Q4 		$1.35M Buy
350,773
+67,761
+24% +$271K ﹤0.01% 4697
2022
Q3 		$1.36M Buy
283,012
+77,444
+38% +$561K ﹤0.01% 4677
2022
Q2 		$1.63M Buy
205,568
+119,703
+139% +$1.13M ﹤0.01% 4684
2022
Q1 		$1.26M Buy
85,865
+15,022
+21% +$238K ﹤0.01% 4840
2021
Q4 		$1.43M Sell
70,843
-14,014
-17% -$338K ﹤0.01% 4830
2021
Q3 		$2.3M Sell
84,857
-164,670
-66% -$4.22M ﹤0.01% 4455
2021
Q2 		$6.08M Buy
249,527
+45,300
+22% +$1.05M ﹤0.01% 3583
2021
Q1 		$4.99M Buy
204,227
+94,416
+86% +$2.74M ﹤0.01% 3406
2020
Q4 		$3.52M Buy
109,811
+99,320
+947% +$3.25M ﹤0.01% 3645
2020
Q3 		$346K Sell
10,491
-2,094
-17% -$90.6K ﹤0.01% 4824
2020
Q2 		$589K Buy
+12,585
New +$478K ﹤0.01% 4519

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley's ADCT Position: Q1 2026 in Review

Morgan Stanley increased its ADC Therapeutics (ADCT) stake by 1.1% in Q1 2026, buying an estimated $169K and bringing the position to 3,812,582 shares worth $14.3M. The position accounts for ﹤0.01% of the portfolio, ranked #3259.

Morgan Stanley first reported a position in ADCT in Q2 2020 and has held it in 24 quarters since. The position peaked at $14.7M in Q3 2025. 118 funds tracked by Wall St. Rank hold ADCT as of Q1 2026.

  • Morgan Stanley held 3,812,582 shares of ADC Therapeutics worth $14.3M as of Q1 2026.
  • Morgan Stanley bought 42,839 ADC Therapeutics shares in Q1 2026, an estimated $169K.
  • ADC Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #3259 holding.
  • Morgan Stanley first reported a position in ADC Therapeutics in Q2 2020 and has held it in 24 quarters since.
  • Morgan Stanley's ADC Therapeutics position peaked at $14.7M in Q3 2025.
  • 118 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.